PegBio Co., Ltd. (HKG:2565)
Hong Kong · Delayed Price · Currency is HKD 5.88
-0.01 (-0.17%)
Aug 27, 2026, 4:08 PM HKT
PegBio Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
53
Market Cap
2.30B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 242.40K | 133.56K | 122.72% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 2.00B |
| AIM Vaccine | 1.30B |
| Shandong Boan Biotechnology | 873.36M |
| Antengene Corporation | 652.54M |
| BioDlink International Company | 582.45M |
| Guangzhou Innogen Pharmaceutical Group | 146.34M |
| Laekna | 118.76M |
| Clover Biopharmaceuticals | 3.90M |